Immucell (ICCC) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to -$139748.0.
- Immucell's Income from Continuing Operations rose 8008.41% to -$139748.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 16097.25%. This contributed to the annual value of -$2.2 million for FY2024, which is 6265.32% up from last year.
- Latest data reveals that Immucell reported Income from Continuing Operations of -$139748.0 as of Q3 2025, which was up 8008.41% from $501880.0 recorded in Q2 2025.
- Immucell's Income from Continuing Operations' 5-year high stood at $1.4 million during Q1 2025, with a 5-year trough of -$2.3 million in Q1 2023.
- Over the past 5 years, Immucell's median Income from Continuing Operations value was -$441303.0 (recorded in 2021), while the average stood at -$457589.9.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 234979.9% in 2022, then surged by 43046.1% in 2025.
- Immucell's Income from Continuing Operations (Quarter) stood at $74134.0 in 2021, then tumbled by 2349.8% to -$1.7 million in 2022, then soared by 31.66% to -$1.1 million in 2023, then surged by 145.14% to $514555.0 in 2024, then crashed by 127.16% to -$139748.0 in 2025.
- Its last three reported values are -$139748.0 in Q3 2025, $501880.0 for Q2 2025, and $1.4 million during Q1 2025.